RxDoctor Payments Data

Hetalben Makwana, MD

Internal Medicine · Rancho Cucamonga, CANPI 1093028078

Payments from drug & device makers

$1,082in general payments, 2019–2025

Across 49 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$149
  • Astellas Pharma US Inc$118
  • AstraZeneca$118
  • Aurinia Pharma U.S., Inc.$96
  • Sanofi-aventis U.S. LLC$74
  • Exact Sciences$62
  • plus $464 from 16 others

What the payments were for

  • Food & beverage$93386%
  • Education$14914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,082 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$69,012
Medicare patients
184
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$106,914
OzempicSemaglutide109$104,394
JardianceEmpagliflozin59$63,350
XareltoRivaroxaban31$47,782
JanuviaSitagliptin Phosphate33$36,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,391
JanumetSitagliptin Phos/Metformin Hcl16$20,855
FarxigaDapagliflozin Propanediol12$16,034
EntrestoSacubitril/Valsartan16$15,913
InvokanaCanagliflozin20$15,453
TrulicityDulaglutide14$11,950
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$7,751
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,597
Fiasp FlextouchInsulin Aspart (Niacinamide)13$6,800
Atorvastatin Calcium627$5,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$20$108,344157 claims
Novo NordiskOzempic$19$104,394109 claims
Boehringer IngelheimJardiance$29$63,35059 claims
Johnson & JohnsonXarelto, Invokana$17$63,23551 claims
MerckJanuvia, Janumet$33$57,74249 claims
GSKTrelegy Ellipta, Breo Ellipta$16$26,70842 claims
AstraZenecaFarxiga$118$16,03412 claims
AbbVieSynthroid$59$3,17348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rancho Cucamonga

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →